Quia Pharma AB (publ) (STO:QUIA)

Market Cap	6.68M
Revenue (ttm)	460.00K
Net Income (ttm)	-33.38M
Shares Out	1.97B
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,549,151
Average Volume	18,920,656
Open	0.0034
Previous Close	0.0034
Day's Range	0.0032 - 0.0040
52-Week Range	0.0025 - 0.0750
Beta	0.44
RSI	52.52
Earnings Date	Aug 22, 2025

About Akoya Biosciences

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform. The company was formerly known as QuiaPEG Pharma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QUIA

Financial Performance

In 2024, Quia Pharma AB's revenue was 460,000, a decrease of -89.48% compared to the previous year's 4.37 million. Losses were -33.38 million, 102.0% more than in 2023.